



# Yemen

Eastern Mediterranean Region




## I. Epidemiological profile

Population (UN)	2016	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	10,612,000	38	Plasmodium species: <i>P. falciparum</i> (99%), <i>P. vivax</i> (1%)
Low transmission (0-1 cases per 1000 population)	7,171,900	26	Major anopheles species: <i>An. arabiensis</i> , <i>An. culicifacies</i> , <i>An. sergentii</i>
Malaria-free (0 cases)	9,792,100	35	Reported confirmed cases (health facility): 98,701    Estimated cases: [287,100–647,000]
Total	27,584,000		Confirmed cases at community level: -    Reported deaths: 65    Estimated deaths: 1,100 [≤ 100–2,200]


## II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	2002	First-line treatment of unconfirmed malaria	AS+SP	2009					
	ITNs/ LLINs distributed to all age groups	Yes	2009	First-line treatment of <i>P. falciparum</i>	AS+SP	2009					
IRS	IRS is recommended	Yes	2001	Treatment failure of <i>P. falciparum</i>	AL	2009					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	QN; AM	2009					
Larval control	Use of larval control recommended	Yes	2002	Treatment of <i>P. vivax</i>	CQ+PQ(14d)	-					
IPT	IPT used to prevent malaria during pregnancy	N/A	-	Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.50 mg/Kg (14 days)					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2001	Type of RDT used		P.f + P.v, P.o, P.m (Combo)					
	Malaria diagnosis is free of charge in the public sector	Yes	2002								
Treatment	ACT is free of charge for all ages in public sector	Yes	2009	<b>Therapeutic efficacy tests (clinical and parasitological failure, %)</b>							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Is banned	-	Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	2016	AL	2010-2013	0	0.55	1.1	28 days	2	<i>P. falciparum</i>
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	2001	AS+SP	2010-2014	0	0	3.6	28 days	5	<i>P. falciparum</i>
	G6PD test is a requirement before treatment with primaquine	Yes	2009	<b>Insecticide resistance tests (mosquito mortality, %)</b>							
	Directly observed treatment with primaquine is undertaken	No	-	Insecticide class	Years	Min	Mean	Max	No. of sites	Species	
	System for monitoring adverse reactions to antimalarials exists	No	-	Organochlorines	2010-2016	0.8	0.9	1	11	<i>An. arabiensis</i>	
Surveillance	ACD for case investigation (reactive)	Yes	2006	Carbamates	2010-2016	1	1	1	11	<i>An. arabiensis</i>	
	ACD of febrile cases at community level (pro-active)	No	-	Pyrethroids	2010-2016	0.5	0.9	1	15	<i>An. arabiensis</i> , <i>An. culicifacies</i> s.l.	
	Mass screening is undertaken	Yes	2001								
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-								
	Foci and case investigation undertaken	-	-								
Case reporting from private sector is mandatory	No	-									



## III. Financing



## Government expenditure by intervention in 2016



## IV. Coverage



## V. Impact

